Trial Profile
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 30 Oct 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 30 Oct 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 13 May 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.